[
    {
        "chunk_id": "dsa700_chunk_0",
        "document_id": "dsa700",
        "text": "Guidelines for the management \nof hypertension in patients with \ndiabetes mellitus\nQuick reference guide\nIn the Eastern Mediterranean Region, there has been a rapid increase in the incidence \nof diabetes mellitus, mainly of type 2. It is now the fourth leading cause of death in the \nRegion and an estimated 22 million people have diabetes out of a total adult population \nof 290 million. This quick reference guide aims to provide a readily accessible overview \nof the evidence-based facts regarding the management of hypertension patients with \ndiabetes mellitus. They have been formulated to help improve the detection and \nmanagement of hypertension in patients with diabetes mellitus, and hence decrease the \nassociated microvascular and macrovascular complications.\nRationale\n\u2022",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_1",
        "document_id": "dsa700",
        "text": "associated microvascular and macrovascular complications.\nRationale\n\u2022 \nMacrovascular disease constitutes the major cause of diabetes mellitus mortality, with 80% \nof patients having and/or dying of cardiovascular, cerebrovascular or peripheral arterial \ndisease. Patients with diabetes exhibit a two to four-fold increase in risk of coronary events \ncompared to non-diabetic individuals.\n\u2022 \nAlthough large-scale studies have shown a clear association between improvement in glycaemic \ncontrol and reduction in microvascular end-organ damage (retinopathy, nephropathy and \nneuropathy), they have not been able to show a consistent similar relationship between \nglycaemic control and macrovascular complications. \n\u2022",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_2",
        "document_id": "dsa700",
        "text": "glycaemic control and macrovascular complications. \n\u2022 \nMany trials, however, have shown a benefit with respect to cardiovascular events, morbidity \nand mortality when coexistent hypertension is treated. In addition, control of hypertension \nis also beneficial to microvascular complications. \n\u2022 \nThis issue is of paramount importance since close to 60% of patients with diabetes are known \nto have hypertension. Therefore, aggressive strategies aimed at identifying and treating high \nblood pressure in patients with diabetes should lead to substantial reduction in the risk of \ncardiovascular morbidity and mortality.\n\u2022 \nIt is important to emphasize that hypertension is but one element of the metabolic syndrome",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_3",
        "document_id": "dsa700",
        "text": "\u2022 \nIt is important to emphasize that hypertension is but one element of the metabolic syndrome \nin patients with type 2 diabetes mellitus. Due attention should be given to other coexisting \ncardiovascular risk factors \u2013 such as obesity and dyslipidaemia \u2013 and appropriate management \nof these conditions should be instituted.\nDefinition and diagnosis of diabetes\nDefinition\n\u2022 \nDiabetes mellitus is a metabolic disorder of multiple etiology, characterized by chronic \nhyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting \nfrom defects in insulin secretion, insulin action, or both.\n\u2022 \nThe effects of diabetes mellitus include long-term damage, dysfunction and failure of various \norgans.\nDiagnosis\n\u2022",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_4",
        "document_id": "dsa700",
        "text": "organs.\nDiagnosis\n\u2022 \nThe diagnosis of diabetes in an asymptomatic individual should never be made on the \nbasis of a single abnormal glucose value. Verification of the diagnosis with repeat testing \nis required, unless an individual presents with unequivocal hyperglycaemia, along with its \nclassic symptoms.\n\u2022 \nThe following table outlines the diagnostic values for diabetes mellitus and other categories \nof hyperglycaemia.\n2\nDiagnostic values for diabetes mellitus and other categories\nof hyperglycaemia\n   \nVenous plasma glucose concentration\n   \nmmol/L \nmg/dL\n Diabetes mellitus \n  fasting or \n\u22657.0 \n\u2265126\n  2-hour post-75 g glucose load \n\u226511.1 \n\u2265200\n IGT\n  fasting (if measured) and \n<7.0 \n<126\n  2-hour post-75 g glucose load \n\u22657.8 and <11.1 \n\u2265140 and <200\n IFG\n  fasting and (if measured)",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_5",
        "document_id": "dsa700",
        "text": "2-hour post-75 g glucose load \n\u22657.8 and <11.1 \n\u2265140 and <200\n IFG\n  fasting and (if measured) \n\u22655.6 and <7.0 \n\u2265100 and <126\n  2-hour post-75 g glucose load \n<7.8 \n<140\nIGT: impaired glucose tolerance\nIFG: impaired fasting glucose\nDefinition and diagnosis of hypertension\nDefinition\n\u2022 \nHypertension is defined as a blood pressure \u2265140/90 mmHg.\n\u2022 \nPrehypertension refers to systolic blood pressure 120\u2013139 mmHg or diastolic 80\u201389 mmHg.\n\u2022 \nNormal blood pressure is referred to as <120/80 mmHg.\nClassification of hypertension\nBP classification \nSBP (mmHg) \n \nDBP (mmHg)\nNormal \n<120 \nand \n<80\nPrehypertension \n120\u2013139 \nor \n80\u201389\nStage 1 hypertension \n140\u2013159 \nor \n90\u201399\nStage 2 hypertension \n\u2265160 \nor \n\u2265100\nSBP: systolic blood pressure\nDBP: diastolic blood pressure\nDiagnosis\n\u2022",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_6",
        "document_id": "dsa700",
        "text": "\u2265160 \nor \n\u2265100\nSBP: systolic blood pressure\nDBP: diastolic blood pressure\nDiagnosis\n\u2022 \nDiagnosis should be made based on the mean of two or more blood pressure measurements, \nmade while the patient is in the seated position.\n\u2022 \nThe possibility of secondary hypertension should be kept in mind and appropriate laboratory \ninvestigation undertaken as indicated.\n3\nRisks associated with hypertension\n\u2022 \nPeople with diabetes and hypertension have a two-fold increased risk of cardiovascular \nmortality compared to patients with diabetes alone.  In addition, they have an increased \nrisk of retinopathy and nephropathy. \n\u2022 \nLowering the blood pressure has been shown to have a beneficial effect on these complications.",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_7",
        "document_id": "dsa700",
        "text": "\u2022 \nLowering the blood pressure has been shown to have a beneficial effect on these complications. \nIt has been shown that each 10 mmHg decrease in systolic blood pressure leads to a decrease \nin diabetes-related mortality by 15%, diabetes-related complications by 12% and myocardial \ninfarctions by 11%.\n\u2022 \nMultiple metabolic abnormalities associated with insulin resistance and increased \ncardiovascular risk such as dyslipidaemia, obesity and hypertension are already present at \ndiagnosis. Consequently, treatment of hyperglycaemia alone cannot be expected to normalize \nthe two to four-fold increased risk of cardiovascular mortality of these patients. \n\u2022 \nIn keeping with this, results of many intervention studies have demonstrated marked benefit",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_8",
        "document_id": "dsa700",
        "text": "\u2022 \nIn keeping with this, results of many intervention studies have demonstrated marked benefit \nfrom antihypertensive, lipid-lowering and antiplatelet therapy. Earlier recognition of at-risk \nindividuals with screening and the subsequent investigation of a wide spectrum of preventive \nand corrective measures are recommended.\nObjectives of diabetes mellitus therapy\n\u2022 \nThe objectives of therapy for diabetes mellitus are:\n\u2212 to eliminate symptoms of hyperglycaemia\n\u2212 to achieve optimum control\n\u2212 to reduce or eliminate microvascular and macrovascular complications\n\u2212 to treat associated disorders\n\u2212 to allow the patient to achieve as normal a lifestyle as possible.\n\u2022 \nThe markers for diabetes control are blood glucose and HbA1c. The recommended goals are \nshown in the following table.",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_9",
        "document_id": "dsa700",
        "text": "shown in the following table.\nOptimal control indicators for management of diabetes mellitus \nGlycaemic control indicator \nNormal \nTarget \nAction needed\nPlasma values\nPre-meal glucose, mg/dL \n<110 \n90\u2013130 \n<90 or >150\n   \nmmol/L \n<6.1 \n5.0\u20137.2 \n<5.0 or >8.3\nBedtime glucose, mg/dL \n<120 \n110\u2013150 \n<110 or >180\n   \nmmol/L \n<6.7 \n6.1\u20138.3 \n<6.1 or >10.0\nWhole blood values \nPre-meal glucose, mg/dL \n<100 \n80\u2013120 \n<80 or >140\n   \nmmol/L \n<5.5 \n4.4\u20136.7 \n<4.4 or >7.8\nBedtime glucose, mg/dL \n<110 \n100\u2013140 \n<100 or >160\n   \nmmol/L \n<6.1 \n5.5\u20137.8 \n<5.5 or >8.9\nHbA1c (%) \n \n<6.0 \n<7.0 \n>8.0\nSelf-monitoring of blood glucose (SMBG) should be available for all people diagnosed with \ndiabetes, as an integral part of self-management education.\n4\n\u2022",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_10",
        "document_id": "dsa700",
        "text": "diabetes, as an integral part of self-management education.\n4\n\u2022 \nThe following table shows the recommendations for metabolic and non-metabolic targets \n(lipid profile, body mass index, blood pressure) for diabetic patients.\nRecommendations for metabolic and non-metabolic targets\n   \nGood \nBorderline  \nPoor\nTotal cholesterol, mg/dL (mmol/L) \n<200 (5.2) \n200\u2013250 (5.2\u20136.5) \n>250 (6.5)\nFasting triglycerides, mg/dL (mmol/L) \n<150 (1.7) \n150\u2013200 (1.7\u20132.2) \n>200 (2.2)\nHDL-cholesterol, mg/dL (mmol/L)  \n \n \n male \n>45 (1.15) \n35\u201345 (0.9\u20131.15) \n<35 (0.9)\n female \n>55 (1.40) \n45\u201355 (1.15\u20131.40) \n<45 (1.15)\nLDL cholesterol mg/dL (mmol/L) \n<100 (2.56) 100\u2013130 (2.56\u20133.33) \n>130 (3.33)\nTotal cholesterol/HDL ratio \n \n \n male \n<6.4 \n \n female \n<5.6 \n \n \nBody mass index (kg/m2) \n \n \n male \n<25.0 \n25.0\u201327.0",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_11",
        "document_id": "dsa700",
        "text": "male \n<6.4 \n \n female \n<5.6 \n \n \nBody mass index (kg/m2) \n \n \n male \n<25.0 \n25.0\u201327.0 \n>27.0\n female \n<24.0 \n24.0\u201326.0 \n>26.0\nBlood pressure (mmHg) \n<130/80\nLDL: low-density lipid\nHDL: high-density lipid\nBlood pressure goal\n\u2022 \nThere is no threshold for the risk of cardiovascular disease, but rather a continuous decrease \nin risk as blood pressure is reduced.\n\u2022 \nThe Hypertension Optimal Treatment (HOT) trial, the United Kingdom Prospective Diabetes \nStudy (UKPDS) and the Appropriate Blood Pressure Control in Diabetes (ABCD) study showed a \nconsistent benefit on cardiovascular events or mortality when blood pressure is reduced.\n\u2022 \nBased on the above trials and on recommendations from international organizations, it is",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_12",
        "document_id": "dsa700",
        "text": "\u2022 \nBased on the above trials and on recommendations from international organizations, it is \nnow accepted that the goal blood pressure level in diabetes mellitus should be <130/80 \nmmHg.\nScreening for hypertension\nFor screening purposes, the following guidelines are recommended.\n\u2022 \nThe patient\u2019s blood pressure should be checked at each clinic visit.\n\u2022 \nOrthostatic measurements are indicated if autonomic neuropathy is suspected.\n\u2022 \nIf blood pressure is found to be \u2265130/80 mmHg, it should be repeated on a separate \nvisit.\n\u2022 \nIf the diagnosis is confirmed, treatment should be started.\n5\nTreatment recommendations\nSuggested protocol for management of hypertension\nManagement\nThe following recommendations apply to the management of hypertension in patients with \ndiabetes.\n\u2022",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_13",
        "document_id": "dsa700",
        "text": "diabetes.\n\u2022 \nLifestyle modification (exercise, healthy diet, reducing weight and sodium intake) can lower \nblood pressure. Smoking cessation should be highly recommended.\n\u2022 \nThiazide diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor \nblockers (ARBs) and \u00df-blockers are good initial therapy options in the treatment of \nuncomplicated hypertension (i.e. no evidence of nephropathy). They have been shown to \nlower cardiovascular events.\n\u2022 \nCalcium channel blockers and \u03b1-blockers can be used, but preferably as second-line \ntherapy.\n\u2022 \nCombination drug therapy is needed in a large number of patients in order to achieve target \nblood pressure.\n\u2022 \nIn patients with microalbuminuria in addition to hypertension, ACE inhibitors or ARBs are",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_14",
        "document_id": "dsa700",
        "text": "\u2022 \nIn patients with microalbuminuria in addition to hypertension, ACE inhibitors or ARBs are \nthe drugs of choice because they have been shown to prevent or slow down the progression \nto macroalbuminuria.\n6\n\u2022 \nIn patients with hypertension and congestive heart failure, ACE inhibitors are beneficial.\n\u2022 \n\u00df-blockers are especially useful in patients with hypertension, post-myocardial infarction.\n\u2022 \nIn patients with nephropathy, careful follow-up of serum creatinine and potassium is \nrecommended if diuretics, ACE inhibitors or ARBs are used.\n\u2022 \nIn the elderly, blood pressure should be lowered in a gradual fashion and over a longer \nperiod of time in order to avoid complications related to organ hypoperfusion.\n\u2022",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_15",
        "document_id": "dsa700",
        "text": "period of time in order to avoid complications related to organ hypoperfusion.\n\u2022 \nAspirin therapy (75\u2013162 mg/day) is indicated as a secondary prevention in patients with \nevidence of cardiovascular disease. It is also indicated as primary prevention for cardiovascular \ndisease in patients at risk, such as age >40, or with hypertension, smoking, obesity, and \ndyslipidaemia.\nConclusion\n\u2022 \nThe following recommendations are made for the management of hypertension in patients \nwith diabetes mellitus:\n\u2212 check blood pressure at each patient visit\n\u2212 target blood pressure level in all patients should be <130/80 mmHg\n\u2212 aggressively pursue management in order to achieve goals.\n\u2022 \nGoal attainment should lead to a decrease in diabetes complications.\n\u2022",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_16",
        "document_id": "dsa700",
        "text": "\u2022 \nGoal attainment should lead to a decrease in diabetes complications.\n\u2022 \nThe care of an individual with diabetes requires a multidisciplinary team. Central to the \nsuccess of this team are the patient\u2019s participation, input, and enthusiasm. Members of the \nhealth team include primary care provider and/or diabetologists, nutritionist, and a diabetes \neducator.\n\u2022 \nWhen the complications of diabetes mellitus arise, sub-specialists including neurologists, \npodiatrists, nephrologists, vascular surgeon, cardiologists and ophthalmologists are \nessential.\n\u2022 \nComprehensive diabetes mellitus care therefore means that optimal diabetes therapy involves \nmore than plasma glucose management. It should also detect and manage diabetes mellitus",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_17",
        "document_id": "dsa700",
        "text": "more than plasma glucose management. It should also detect and manage diabetes mellitus \ncomplications and modify diabetes mellitus-related risk factors.\n\u2022 \nThe management of hypertension is only one of multiple strategies recommended by WHO \nfor patients with diabetes. Further objectives of diabetes prevention and care include:\n\u2212 promotion of a healthy lifestyle\n\u2212 increasing community awareness about diabetes\n\u2212 primary diabetes prevention\n\u2212 development of national strategies for control of diabetes, obesity, hypertension and \ndyslipidaemia.\n7\nFurther reading\nChobanian AV, et al. Seventh report of the Joint National Committee on prevention, detection, \nevaluation and treatment of high blood pressure. Hypertension, 2003, 42:1206\u20131252.\nFurther information\nNoncommunicable Diseases Unit",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_18",
        "document_id": "dsa700",
        "text": "Further information\nNoncommunicable Diseases Unit\nWHO Regional Office for the Eastern Mediterranean\nPO Box 7608, Nasr City\nCairo 11371, Egypt\nEmail: NCD@emro.who.int; Website: http://www.emro.who.int/ncd/\nDesign and layout by Ahmed Hassanein\nPrinted by Fikra Advertising Agency\nFor further information, consult Khatib OMN, El-Guindy MS (eds.) Clincial guidelines for \nthe management of hypertension, Cairo, World Health Organization Regional Office for the \nEastern Mediterranean, 2005 (EMRO Technical Publications Series No. 29) and Khatib OMN \n(ed.) Guidelines for the prevention, management and care of diabetes mellitus, Cairo, World \nHealth Organization Regional Office for the Eastern Mediterranean, 2006 (EMRO Technical \nPublications Series No. 32) on which this card is based, or contact:",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "dsa700_chunk_19",
        "document_id": "dsa700",
        "text": "Publications Series No. 32) on which this card is based, or contact: \n978 92 9021 565 3",
        "metadata": {
            "year": "2020",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    }
]